Vesiflo

Executive Summary

Vesiflo is a private medical device company headquartered in San Francisco, focused on urology and addressing chronic urinary retention in women. Its flagship product, the inFlow device, is an innovative intraurethral valve-pump that enables catheter-free bladder emptying, offering a potential paradigm shift in patient comfort and quality of life. Complementing the hardware, the Guardian Program is a digital health platform designed for remote patient monitoring and clinical data management, which could enhance treatment outcomes and streamline physician workflows. Founded in 2019, Vesiflo operates in a large and underserved market, as millions of women suffer from chronic retention and rely on catheters that carry infection risks and inconvenience. The company's dual hardware-software approach positions it well for adoption, though it faces regulatory hurdles and competition from established catheter and implantable device players. Vesiflo's early-stage private status suggests it will likely require additional funding to complete pivotal studies and secure FDA clearance.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for inFlow device60% success
• Q2 2027Pivotal clinical trial results publication55% success
• Q3 2026Series B or C funding round announcement70% success